“Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.”, Addiction, vol. 111, no. 8, pp. 1416-27, 2016.
, “Bupropion and Naltrexone in Methamphetamine Use Disorder”, N Engl J Med, vol. 384, no. 2, pp. 140-153, 2021.
, “Care cascade structural intervention versus standard of care in the diagnosis and treatment of HIV in China: a cluster-randomized controlled trial protocol.”, BMC Health Serv Res, vol. 17, no. 1, p. 397, 2017.
, “Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.”, Contemp Clin Trials, vol. 34, no. 2, pp. 196-204, 2013.
, “Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.”, Addiction, vol. 111, no. 4, pp. 695-705, 2016.
, “Loss to Follow-Up from HIV Screening to ART Initiation in Rural China.”, PLoS One, vol. 11, no. 10, p. e0164346, 2016.
, “NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.”, Contemp Clin Trials, vol. 50, pp. 253-64, 2016.
, “Testing and linkage to HIV care in China: a cluster-randomised trial.”, Lancet HIV, vol. 4, no. 12, pp. e555-e565, 2017.
, “Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.”, J Addict Med, vol. 10, no. 4, pp. 236-43, 2016.
,